You have 9 free searches left this month | to do more
Showing 1 - 25 of
688 items
Trials Per Page
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
F
Feasibility Study on Expandion of MILs From NSCLC and SCLC Patients and Infusion With Pembrolizumab
Withdrawn
  • SCLC
  • NSCLC
  • MILs™ in Combination with Pembrolizumab
  • (no location specified)
2021-10-01
Oct 1, 2021
I
RW Effectiveness of Lurbinectedin in Extensive Stage SCLC
Not yet recruiting
  • Small-cell Lung Cancer
  • Paris, France
  • +1 more
2022-03-16
Mar 16, 2022
I
Atezolizumab Combined With Chemotherapy in Extensive Stage SCLC
Recruiting
  • Small Cell Lung Cancer
  • atezolizumab
  • Chalon-sur-Saône, France
  • +1 more
2022-03-04
Mar 4, 2022
F
Effect of Combination Therapy on SCLC After Initial Treatment Failure
Not yet recruiting
  • Small-cell Lung Cancer
    • (no location specified)
    2021-03-08
    Mar 8, 2021
    C
    Study in Patients With SCLC of Veliparib in Combination With Topotecan
    Recruiting
    • Small Cell Lung Cancer SCLC
    • München Gauting, Germany
      Klinik München Gauting
    2021-01-26
    Jan 26, 2021
    J
    Whole Brain Radiation Therapy Alone vs. Radiosurgery for SCLC Patients With 1-10 Brain Metastases
    Recruiting
    • SCLC
    • Brain Metastases
    • SRS
    • WBRT
    • Heidelberg, Germany
      University Hospital of Heidelberg, Department of Radiation Oncol
    2021-09-28
    Sep 28, 2021
    F
    Circulating EV Long RNA Profiles in SCLC
    Recruiting
    • Small Cell Lung Cancer
    • Blood sample collection
    • Shanghai, Shanghai, China
      Cancer hospital Fudan University
    2022-01-10
    Jan 10, 2022
    J
    Safety, Tolerability and Preliminary Efficacy of JK1201I in Patients With SCLC
    Recruiting
    • Small Cell Lung Cancer (SCLC)
    • Beijing, Beijing, China
      Beijing Cancer Hospital
    2021-12-14
    Dec 14, 2021
    X
    Application of ctDNA in the Evaluation of Curative Effect and Prognosis of SCLC Patients
    Not yet recruiting
    • Small Cell Lung Cancer Extensive Stage
    • Observation
    • (no location specified)
    2021-09-22
    Sep 22, 2021
    C
    Safety and Tolerability Evaluation of Low-dose Radiation in Combination With CS1001 in Relapsed SCLC Patients
    Recruiting
    • Relapsed Small Cell Lung Cancer
    • Chendu, Sichuan, China
      West China Hospital, Sichuan University
    2022-02-17
    Feb 17, 2022
    N
    Sequential Hypofractionated Radiotherapy Followed by Anti-PD-L1 Atezolizumab for SCLC
    Recruiting
    • Small Cell Lung Cancer Recurrent
    • Goyang-si, Gyeonggi-do, Korea, Republic of
      National Cancer Center
    2022-04-04
    Apr 4, 2022
    C
    Targeted Therapy With CDK4/6 Inhibitors in Chemo-Refractory, Rb Wild-Type Extensive SCLC
    Recruiting
    • Small-cell Lung Cancer
    • Cleveland, Ohio
      Case Medical Center, University Hospitals Seidman Cancer Center,
    2022-03-14
    Mar 14, 2022
    H
    Tislelizumab Combined With Anlotinib and 2-cycles Irinotecan as Second Line Treatment of SCLC
    Recruiting
    • Small Cell Lung Cancer (SCLC)
    • Anlotinib Tislelizumab Irinotecan
    • Guangzhou, Guangdong, China
      Guangdong Provincial Hospital of Traditional Chinese Medicine
    2021-11-22
    Nov 22, 2021
    H
    Camrelizumab Plus Apatinib as Maintenance Therapy in Extensive-stage Small-cell Lung Cancer
    Recruiting
    • Small Cell Lung Carcinoma
    • Camrelizumab Plus Apatinib
    • Zhengzhou, Henan, China
      Henan Cancer Hospital
    2021-11-24
    Nov 24, 2021
    Z
    A Prospective Study Comparing Two Radiotherapy Dose/Fraction and Omitting CTVs of the Primary Tumor in Limited SCLC
    Recruiting
    • Small Cell Lung Cancer Limited Stage
    • Hyperfractionated radiotherapy
    • +3 more
    • Hangzhou, Zhejiang, China
      Zhejiang Cancer Hospital
    2020-09-02
    Sep 2, 2020
    B
    Treatment Patterns, Clinical Outcomes, and Healthcare Resource Utilization Associated With Chinese Patients With Advanced Lung Cancer - 2020
    Completed
    • Lung Cancer
    • +2 more
      • Shanghai, SHG, China
        Local Institution
      2021-09-07
      Sep 7, 2021
      N
      Lurbinectedin With Berzosertib, an ATR Kinase Inhibitor in Small Cell Cancers and High-Grade Neuroendocrine Cancers
      Recruiting
      • SCLC
      • +3 more
      • Bethesda, Maryland
        National Institutes of Health Clinical Center
      2022-04-07
      Apr 7, 2022
      A
      A Phase 1 Study Evaluating the Safety, Tolerability and Efficacy of AMG 119 in Subjects With RR SCLC
      Suspended
      • Small Cell Lung Cancer
      • AMG 119
      • Tampa, Florida
      • +1 more
      2021-11-29
      Nov 29, 2021
      I
      IBI110 in Combination With Sintilimab and Chemotherapy in Patients With Untreated Extensive-Stage Small Cell Lung Cancer
      Recruiting
      • SCLC
      • Shanghai, Shanghai, China
        Shanghai Pulmonary Hospital
      2021-09-14
      Sep 14, 2021
      H
      Immune Checkpoint Inhibition With Lurbinectedin Relapsed/Recurrent SCLC
      Recruiting
      • Small-cell Lung Cancer
      • +2 more
      • Kissimmee, Florida
      • +1 more
      2022-01-27
      Jan 27, 2022
      A
      Reveal the Patterns of Presentation, Management and Outcome of Patients With SCLC and Stage III NSCLC in Saudi Arabia:
      Recruiting
      • Lung Cancer
        • Riyadh, Saudi Arabia
        • +2 more
        2022-03-23
        Mar 23, 2022
        S
        Pazopanib Maintenance for SCLC - 2017
        Completed
        • SCLC
        • Seoul, Korea, Republic of
          Samsung Medical Center
        2019-12-05
        Dec 5, 2019
        S
        Hippocampal Prophylactic Cranial Irradiation for Small Cell Lung Cancer - 2019
        Completed
        Has Results
        • Small-cell Lung Cancer
        • +2 more
        • Hippocampal-sparing Prophylactic Cranial Irradiation
        • Baltimore, Maryland
        • +1 more
        2021-09-22
        Sep 22, 2021
        A
        APG-1252 in Patients With SCLC or Advanced Solid Tumors - 2021
        Terminated
        • Small Cell Lung Cancer and Other Solid Tumors
        • Guangzhou, Guangdong, China
          Guangdong General Hospital
        2021-08-24
        Aug 24, 2021
        V
        Venetoclax and Irinotecan in Relapsed/Refractory SCLC
        Withdrawn
        • Relapsed Small Cell Lung Cancer
        • Refractory Small Cell Lung Carcinoma
        • Venetoclax 50 MG
        • +6 more
        • (no location specified)
        2021-03-01
        Mar 1, 2021